Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Update

Grace Therapeutics, Inc. (NASDAQ:GRCE) was the recipient of a significant growth in short interest during the month of February. As of February 27th, there was short interest totaling 390,568 shares, a growth of 496.7% from the February 12th total of 65,459 shares. Based on an average daily volume of 180,882 shares, the short-interest ratio is presently 2.2 days. Currently, 2.8% of the company’s stock are sold short. Currently, 2.8% of the company’s stock are sold short. Based on an average daily volume of 180,882 shares, the short-interest ratio is presently 2.2 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Stratos Wealth Partners LTD. bought a new stake in Grace Therapeutics during the fourth quarter worth about $39,000. SeaCrest Wealth Management LLC acquired a new position in shares of Grace Therapeutics in the 3rd quarter valued at approximately $42,000. Millington Financial Advisors LLC bought a new stake in shares of Grace Therapeutics during the 2nd quarter worth approximately $59,000. XTX Topco Ltd acquired a new stake in shares of Grace Therapeutics during the 4th quarter worth approximately $106,000. Finally, Renaissance Technologies LLC boosted its position in shares of Grace Therapeutics by 53.5% during the 4th quarter. Renaissance Technologies LLC now owns 129,781 shares of the company’s stock worth $449,000 after acquiring an additional 45,220 shares in the last quarter. Institutional investors and hedge funds own 6.08% of the company’s stock.

Grace Therapeutics Trading Up 0.5%

GRCE stock traded up $0.02 during mid-day trading on Tuesday, hitting $3.95. 252,281 shares of the company were exchanged, compared to its average volume of 177,260. Grace Therapeutics has a 1-year low of $1.75 and a 1-year high of $4.30. The stock has a market capitalization of $61.11 million, a PE ratio of -9.87 and a beta of 0.71. The business has a 50 day simple moving average of $3.75 and a 200-day simple moving average of $3.36.

Grace Therapeutics (NASDAQ:GRCE) last announced its earnings results on Thursday, February 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.05). Equities research analysts expect that Grace Therapeutics will post -1.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GRCE has been the topic of several recent analyst reports. Wall Street Zen raised Grace Therapeutics to a “hold” rating in a research report on Friday, January 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Grace Therapeutics in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Grace Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $12.00.

About Grace Therapeutics

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.